Literature DB >> 17078951

PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.

Fei Liu1, Zhihou Liang, Jianhua Shi, Dongmei Yin, Ezzat El-Akkad, Inge Grundke-Iqbal, Khalid Iqbal, Cheng-Xin Gong.   

Abstract

Phosphorylation of tau protein is regulated by several kinases, especially glycogen synthase kinase 3beta (GSK-3beta), cyclin-dependent protein kinase 5 (cdk5) and cAMP-dependent protein kinase (PKA). Phosphorylation of tau by PKA primes it for phosphorylation by GSK-3beta, but the site-specific modulation of GSK-3beta-catalyzed tau phosphorylation by the prephosphorylation has not been well investigated. Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396. These studies reveal the nature of the inter-regulation of tau phosphorylation by the three major tau kinases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17078951      PMCID: PMC1828604          DOI: 10.1016/j.febslet.2006.10.033

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  30 in total

Review 1.  Regulation of GSK-3: a cellular multiprocessor.

Authors:  A J Harwood
Journal:  Cell       Date:  2001-06-29       Impact factor: 41.582

2.  Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells.

Authors:  Thilo Hagen; Elena Di Daniel; Ainsley A Culbert; Alastair D Reith
Journal:  J Biol Chem       Date:  2002-04-19       Impact factor: 5.157

3.  Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer disease.

Authors:  E Montejo de Garcini; L Serrano; J Avila
Journal:  Biochem Biophys Res Commun       Date:  1986-12-15       Impact factor: 3.575

4.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.

Authors:  Yousang Gwack; Sonia Sharma; Julie Nardone; Bogdan Tanasa; Alina Iuga; Sonal Srikanth; Heidi Okamura; Diana Bolton; Stefan Feske; Patrick G Hogan; Anjana Rao
Journal:  Nature       Date:  2006-03-01       Impact factor: 49.962

5.  Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain.

Authors:  K Ishiguro; S Kobayashi; A Omori; M Takamatsu; S Yonekura; K Anzai; K Imahori; T Uchida
Journal:  FEBS Lett       Date:  1994-04-04       Impact factor: 4.124

6.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5.

Authors:  A Sengupta; Q Wu; I Grundke-Iqbal; K Iqbal; T J Singh
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

Review 7.  Post-translational modifications of tau protein in Alzheimer's disease.

Authors:  C-X Gong; F Liu; I Grundke-Iqbal; K Iqbal
Journal:  J Neural Transm (Vienna)       Date:  2004-10-27       Impact factor: 3.575

8.  Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356.

Authors:  J M Litersky; G V Johnson; R Jakes; M Goedert; M Lee; P Seubert
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

9.  Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases.

Authors:  T J Singh; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  FEBS Lett       Date:  1995-01-16       Impact factor: 4.124

10.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; William R Markesbery
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

View more
  49 in total

1.  A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.

Authors:  Ya-Li Zheng; Niranjana D Amin; Ya-Fang Hu; Parvathi Rudrabhatla; Varsha Shukla; Jyotshnabala Kanungo; Sashi Kesavapany; Philip Grant; Wayne Albers; Harish C Pant
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Authors:  Annamaria Lanzillotta; Ilenia Sarnico; Marina Benarese; Caterina Branca; Cristina Baiguera; Birgit Hutter-Paier; Manfred Windisch; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  J Mol Neurosci       Date:  2010-12-22       Impact factor: 3.444

3.  Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway.

Authors:  Lin Wang; Bing-Jin Liu; Yun Cao; Wei-Qi Xu; Dong-Sheng Sun; Meng-Zhu Li; Fang-Xiao Shi; Man Li; Qing Tian; Jian-Zhi Wang; Xin-Wen Zhou
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

4.  Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation.

Authors:  Fei Liu; Bin Li; E-Jan Tung; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  Eur J Neurosci       Date:  2007-12-04       Impact factor: 3.386

Review 5.  The "aged garlic extract:" (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer's disease (AD).

Authors:  B Ray; N B Chauhan; D K Lahiri
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies.

Authors:  Lina Adwan; Gehad M Subaiea; Riyaz Basha; Nasser H Zawia
Journal:  J Neurochem       Date:  2014-10-18       Impact factor: 5.372

7.  Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.

Authors:  Jiangnan Peng; Sucheta Kudrimoti; Sivaprakasam Prasanna; Srinivas Odde; Robert J Doerksen; Hari K Pennaka; Yeun-Mun Choo; Karumanchi V Rao; Babu L Tekwani; Vamsi Madgula; Shabana I Khan; Bin Wang; Alejandro M S Mayer; Melissa R Jacob; Lan Chun Tu; Jürg Gertsch; Mark T Hamann
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

Review 8.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

9.  Diacylglycerol kinase β knockout mice exhibit lithium-sensitive behavioral abnormalities.

Authors:  Kenichi Kakefuda; Atsushi Oyagi; Mitsue Ishisaka; Kazuhiro Tsuruma; Masamitsu Shimazawa; Koichi Yokota; Yasuhito Shirai; Kyoji Horie; Naoaki Saito; Junji Takeda; Hideaki Hara
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

Review 10.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.